Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.960
-0.300 (-5.70%)
At close: May 15, 2026, 4:00 PM EDT
4.975
+0.015 (0.30%)
After-hours: May 15, 2026, 6:02 PM EDT
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $251.15K in the quarter ending March 31, 2026, a decrease of -2.61%. This brings the company's revenue in the last twelve months to $7.94M, up 115.44% year-over-year. In the year 2025, Coya Therapeutics had annual revenue of $7.95M with 123.57% growth.
Revenue (ttm)
$7.94M
Revenue Growth
+115.44%
P/S Ratio
14.66
Revenue / Employee
$992,377
Employees
8
Market Cap
116.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.95M | 4.39M | 123.57% |
| Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
| Dec 31, 2023 | 6.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Q32 Bio | 53.74M |
| Verrica Pharmaceuticals | 37.16M |
| Rani Therapeutics Holdings | 1.63M |
| NRx Pharmaceuticals | 1.23M |
| Cardiff Oncology | 593.00K |
COYA News
- 4 days ago - Coya Therapeutics granted FDA Fast Track Designation for COYA 302 - TheFly
- 4 days ago - Coya Therapeutics reports Q1 EPS (32c), consensus (39c) - TheFly
- 4 days ago - Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - Business Wire
- 4 days ago - Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Business Wire
- 5 weeks ago - Coya Therapeutics announces publication of research on COYA 302 - TheFly
- 5 weeks ago - Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS - Business Wire
- 6 weeks ago - Coya Therapeutics Executive Chairman Howard Berman steps down - TheFly
- 6 weeks ago - Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director - Business Wire